Omnicell (OMCL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Apr, 2026Executive summary
The annual meeting is scheduled for May 19, 2026, and will be held virtually via webcast.
Five key proposals are up for shareholder vote, including director elections, executive compensation, equity plan amendment, certificate of incorporation amendment, and auditor ratification.
Only shareholders of record as of March 27, 2026, are eligible to vote.
Voting can be done electronically, by mail, phone, or internet, with detailed procedures for both record and beneficial owners.
Proxy materials and annual reports are available online for shareholder review.
Voting matters and shareholder proposals
Election of three Class I directors to serve until the 2029 annual meeting.
Advisory vote on named executive officer compensation (say-on-pay).
Approval of an amendment to the 2009 Equity Incentive Plan to add 1,600,000 shares.
Amendment to the certificate of incorporation to provide exculpation from personal liability for certain officers and minor updates.
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Shareholder proposals for the 2027 meeting must be submitted by December 14, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Board consists of nine members, divided into three classes with staggered three-year terms.
89% of directors are independent; CEO is not independent.
Board leadership combines CEO and Chairman roles, with a Lead Independent Director providing additional oversight.
Four standing committees: Audit, Compensation, Corporate Governance, and M&A, all with independent members.
Directors and executive officers are subject to stock ownership guidelines.
Board and committee attendance exceeded 75% in 2025.
Latest events from Omnicell
- Proxy seeks approval on director elections, compensation, equity plan, officer exculpation, and auditor.OMCL
Proxy filing2 Apr 2026 - Q4 and FY 2025 revenues and ARR rose, with Titan XT and OmniSphere driving growth and strong 2026 outlook.OMCL
Q4 20255 Feb 2026 - Q2 revenue beat guidance; recurring and Advanced Services growth drove raised 2024 outlook.OMCL
Q2 20242 Feb 2026 - Accelerated innovation and advanced services drive growth, margin expansion, and strategic partnerships.OMCL
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 revenue fell 5% but net income and service revenues rose; 2024 guidance increased.OMCL
Q3 202417 Jan 2026 - XT Amplify and advanced services fuel growth, with specialty pharmacy driving revenue momentum.OMCL
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - AI-powered automation and advanced services are set to drive growth and recurring revenue in 2025.OMCL
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q4 2024 saw 19% revenue growth and strong 2025 guidance driven by innovation and backlog.OMCL
Q4 20246 Jan 2026 - Recurring revenue and SaaS growth drive innovation and financial strength in 2025.OMCL
Investor Presentation15 Dec 2025